Get started
Author

Christoph Weinlinger

Observed names: C. Weinlinger, Weinlinger, C., Weinlinger, Christoph
OpenAlex ID: A5086509508
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
2021 · Oliver Illini, Maximilian Johannes Hochmair, et al. · Therapeutic Advances in Medical Oncology · 45
PDF
Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer
2019 · Eva Obermayr, Christiane Agreiter, et al. · Cells · 43
PDF
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
2022 · Oliver Illini, Hannah Fabikan, et al. · Therapeutic Advances in Medical Oncology · 31
PDF
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
2020 · Maximilian J. Hochmair, Hannah Fabikan, et al. · Pharmaceuticals · 31
PDF
Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
2021 · Eva Obermayr, Nina Koppensteiner, et al. · Journal of Personalized Medicine · 26
PDF
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
2019 · Maximilian Hochmair, Barbara Rath, et al. · Investigational New Drugs · 19
PDF
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
2024 · Oliver Illini, Felix Carl Saalfeld, et al. · International Journal of Molecular Sciences · 12
PDF
Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines
2019 · Maximilian Hochmair, Christoph Weinlinger, et al. · Anti-Cancer Drugs · 11
Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation
2024 · Eva Welsch, Barbara Holzer, et al. · International Journal of Cancer · 10
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
2026 · Oliver Illini, Anna-Carina Hund, et al. · Journal of Thoracic Oncology · 8
PDF
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
2022 · Oliver Illini, Hannah Fabikan, et al. · Journal of Clinical Medicine · 8
PDF
Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient
2019 · Maximilian Hochmair, Christoph Weinlinger, et al. · Anti-Cancer Drugs · 8
Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
2024 · Oliver Illini, Anna Sophie Lang-Stöberl, et al. · Cancer Treatment and Research Communications · 7
Prognostic impact of targetable driver alterations in resected early-stage lung cancer
2024 · Angelika Terbuch, Selma Konjic, et al. · Translational Lung Cancer Research · 6
The Landsteiner lung cancer research platform (LALUCA)
2024 · Anna Lang-Stöberl, Hannah Fabikan, et al. · Wiener klinische Wochenschrift · 6
PDF
Effect of short-term storage of blood samples on gene expression in lung cancer patients
2022 · Eva Obermayr, Nina Koppensteiner, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 5
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma
2024 · Oliver Illini, Michal Benej, et al. · Journal of Clinical Medicine · 4
PDF
Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion–Positive Metastatic Lung Cancer
2019 · Maximilian Johannes Hochmair, Ulrike Setinek, et al. · Clinical Lung Cancer · 4
Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study
2026 · Caroline Braschel, Hannah Fabikan, et al. · Cancers · 3
PDF
Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy
2025 · Oliver Illini, Hannah Fabikan, et al. · Medicine · 2
Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations
2024 · Oliver Illini, Hannah Fabikan, et al. · Journal of Clinical Medicine · 2
PDF
Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients
2020 · Maximilian Johannes Hochmair, Helmut Prosch, et al. · Anti-Cancer Drugs · 2
Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment
2020 · Maximilian Johannes Hochmair, Christoph Weinlinger, et al. · Anti-Cancer Drugs · 2
Very First Real-World Data on Zongertinib Use in Non-Small Cell Lung Cancer Patients with Her2 Mutations: A Brief Report
2024 · Oliver Illini, Anna Sophie Lang-Stöberl, et al. · SSRN Electronic Journal · 1
EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
2022 · O. Illini, H. Fabikan, et al. · Journal of Thoracic Oncology · 1
Works count: 42
Citation count: 298
H-index: 9
I10-index: 9
Year
Topic
Type